LEPR Specific Neutra™ Antibody Products

Struggling with prolonged drug development timelines or challenges in targeting leptin receptor (LEPR) signaling? Creative Biolabs' LEPR-specific Neutra™ antibody products accelerate your research with advanced epitope-specific engineering, enabling precise modulation of LEPR activity for metabolic disease therapeutics and high-throughput assay development.

Introduction to LEPR

The LEPR, a class I cytokine receptor, mediates leptin signaling to regulate energy homeostasis, appetite, and immune responses. Expressed predominantly in the hypothalamus, LEPR exists as multiple splice variants, with the long isoform (LEPRb) essential for intracellular signaling. Its dysregulation is linked to metabolic disorders, making it a pivotal therapeutic target.

• Structure

LEPR comprises an extracellular ligand-binding domain, a transmembrane region, and an intracellular domain responsible for signal transduction. The extracellular domain contains two cytokine receptor homology regions (CRH1 and CRH2) and an immunoglobulin-like domain, which collectively enable high-affinity leptin binding. Structural studies reveal that leptin-LEPR interaction induces receptor dimerization, activating downstream pathways.

• Related Signaling Pathways

LEPR signaling primarily engages the JAK-STAT pathway: leptin binding triggers JAK2 phosphorylation, recruiting STAT3/5 to regulate gene expression. Additionally, LEPR activates MAPK/ERK and PI3K-AKT pathways, influencing cell proliferation and metabolism. These pathways intersect with insulin and inflammatory signaling, underscoring LEPR's role in metabolic integration.

Fig.1 LEPR receptor signaling pathways.¹

• Associated Diseases

LEPR dysfunction underlies obesity, type 2 diabetes, and hypothalamic amenorrhea. Loss-of-function mutations cause severe early-onset obesity, while leptin resistance—common in metabolic syndrome—drives chronic inflammation and insulin dysregulation. Targeting LEPR offers therapeutic potential to restore metabolic balance.

Applications of LEPR Neutralizing Antibodies

• Metabolic Disease Research

LEPR-neutralizing antibodies elucidate mechanisms of leptin resistance in obesity. By blocking leptin-LEPR interaction, researchers simulate metabolic dysfunction in vitro, identifying novel therapeutic targets to reverse insulin resistance.

• Therapeutic Candidate Screening

Antibodies serve as benchmark tools in high-throughput screens for LEPR agonists/antagonists. Competitive binding assays using our antibodies validate drug candidates' efficacy in restoring leptin sensitivity.

• Diagnostic Assay Development

LEPR-specific antibodies enable quantitative assays for leptin receptor levels in patient sera, correlating with disease progression. These diagnostics aid in stratifying patients for targeted therapies.

• Preclinical Efficacy Testing

In vivo models of diet-induced obesity treated with neutralizing antibodies demonstrate restored metabolic parameters, supporting translational applications. Antibodies also validate gene therapies aiming to upregulate LEPR expression.

Our Anti-LEPR Antibodies

Creative Biolabs' anti-LEPR antibodies are engineered for high specificity to extracellular domains, enabling:

- Quantitative detection: Reliable measurement of LEPR expression in tissues or serum via ELISA or Western blot.

- Functional modulation: Neutralizing antibodies block leptin binding, facilitating studies on receptor-ligand dynamics.

- Mechanistic studies: Antibodies with epitopes targeting CRH2 inhibit JAK-STAT activation, clarifying pathway crosstalk.

Validated across human, mouse, and rat models, these antibodies exhibit >95% purity and nanomolar affinity, ensuring reproducibility in preclinical research.

Creative Biolabs offers LEPR-specific Neutra™ antibody products with unparalleled specificity and reliability for metabolic research and drug development. With customizable formats for ELISA, flow cytometry, and functional assays, our antibodies empower breakthroughs in targeting leptin signaling.

Contact our team today to discuss your project requirements and explore tailored solutions.

REFERENCE

1. Vilariño-García, Teresa, et al. "Role of leptin in obesity, cardiovascular disease, and type 2 diabetes." International journal of molecular sciences 25.4 (2024): 2338. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms25042338